Effect of FTY720-phosphate on the expression of inflammation-associated molecules in astrocytes in vitro

Janssen,Stefanie; Schlegel,Caroline; Gudi,Viktoria; Prajeeth,Chittappen  Kandiyil; Skripuletz,Thomas; Trebst,Corinna; Stangel,Martin

doi:10.3892/mmr.2015.4120

Effect of FTY720-phosphate on the expression of inflammation-associated molecules in astrocytes in vitro

Authors:
- Stefanie Janssen
- Caroline Schlegel
- Viktoria Gudi
- Chittappen Kandiyil Prajeeth
- Thomas Skripuletz
- Corinna Trebst
- Martin Stangel
View Affiliations

Affiliations: Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover D‑30625, Germany
Published online on: July 27, 2015 https://doi.org/10.3892/mmr.2015.4120
Pages: 6171-6177

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

FTY720 is a new oral immunomodulatory therapy for the treatment of multiple sclerosis (MS). There is strong evidence that FTY720 has direct effects on brain resident cells such as astrocytes acting via sphingosine‑1‑phosphate (S1P) receptors. In the present study, the mRNA expression of S1P receptors as well as selected cytokines, chemokines and growth factors were investigated in primary murine astrocytes under inflammatory conditions in the presence or absence of the phosphorylated form of FTY720 (FTY720‑P). Following stimulation with either the pro‑inflammatory cytokine tumor necrosis factor‑α (TNF‑α) or with bacterial lipopolysaccharide, there was an increased expression of the receptors S1P1 and S1P3, the cytokines and chemokines interleukin (IL)‑1β, chemokine (C‑C‑motif) ligand 2 (CCL‑2), CCL‑20 and chemokine (C‑X‑C‑motif) ligand 12 as well as the growth factors insulin‑like growth factor‑1, ciliary neurotrophic factor and glial cell line‑derived neurotrophic factor (GDNF). FTY720‑P led to an increased expression of IL‑1β and GDNF at distinct time points following co‑stimulation with TNF‑α compared with TNF‑α treatment alone. However, the presence of FTY720‑P did not have any further significant effects on the expression of S1P receptors, cytokines or growth factors, suggesting that the regulation of these target genes in astrocytes is not likely to be a major mechanism underlying the effect of FTY720‑P in diseases such as MS.

View Figures

View References

1	Goldschmidt T, Antel J, König FB, Brück W and Kuhlmann T: Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 72:1914–1921. 2009. View Article : Google Scholar : PubMed/NCBI
2	Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C and Lassmann H: Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 129:3165–3172. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362:402–415. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L and Burtin P; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362:387–401. 2010. View Article : Google Scholar : PubMed/NCBI
5	Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY and Hla T: Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquiti-nylation and proteasomal degradation of the receptor. J Biol Chem. 282:9082–9089. 2007. View Article : Google Scholar : PubMed/NCBI
6	Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, et al: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 296:346–349. 2002. View Article : Google Scholar : PubMed/NCBI
7	Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 427:355–360. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chun J, Weiner JA, Fukushima N, Contos JJ, Zhang G, Kimura Y, Dubin A, Ishii I, Hecht JH, Akita C, et al: Neurobiology of receptor-mediated lysophospholipid signaling. From the first lysophospholipid receptor to roles in nervous system function and development. Ann NY Acad Sci. 905:110–117. 2000. View Article : Google Scholar : PubMed/NCBI
9	Rao TS, Lariosa-Willingham KD, Lin FF, Palfreyman EL, Yu N, Chun J and Webb M: Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res. 990:182–194. 2003. View Article : Google Scholar : PubMed/NCBI
10	Spiegel S and Milstien S: Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol. 4:397–407. 2003. View Article : Google Scholar : PubMed/NCBI
11	Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M and Billich A: Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 323:469–475. 2007. View Article : Google Scholar : PubMed/NCBI
12	Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, et al: FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA. 108:751–756. 2011. View Article : Google Scholar :
13	Mullershausen F, Craveiro LM, Shin Y, Cortes-Cros M, Bassilana F, Osinde M, Wishart WL, Guerini D, Thallmair M, Schwab ME, et al: Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem. 102:1151–1161. 2007. View Article : Google Scholar : PubMed/NCBI
14	Osinde M, Mullershausen F and Dev KK: Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology. 52:1210–1218. 2007. View Article : Google Scholar : PubMed/NCBI
15	Sun H, Bénardais K, Stanslowsky N, Thau-Habermann N, Hensel N, Huang D, Claus P, Dengler R, Stangel M and Petri S: Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in Amyotrophic Lateral Sclerosis (ALS) - in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. PLoS One. 8:e729262013. View Article : Google Scholar :
16	Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M and Illgen-Wilcke B; FELASA (Federation of European Laboratory Animal Science Associations Working Group on Health Monitoring of Rodent and Rabbit Colonies): Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 36:20–42. 2002. View Article : Google Scholar : PubMed/NCBI
17	Pébay A, Toutant M, Prémont J, Calvo CF, Venance L, Cordier J, Glowinski J and Tencé M: Sphingosine-1-phosphate induces proliferation of astrocytes: Regulation by intracellular signalling cascades. Eur J Neurosci. 13:2067–2076. 2001. View Article : Google Scholar : PubMed/NCBI
18	Yoshida Y, Nakada M, Sugimoto N, Harada T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Yachie A, Takuwa Y, et al: Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer. 126:2341–2352. 2010.
19	Sheridan GK and Dev KK: S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia. 60:382–392. 2012. View Article : Google Scholar
20	Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, Lakeman K, Dijkstra CD, Van Der Valk P, Reijerkerk A, et al: Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 58:1465–1476. 2010.PubMed/NCBI
21	Wu C, Leong SY, Moore CS, Cui QL, Gris P, Bernier LP, Johnson TA, Séguéla P, Kennedy TE, Bar-Or A, et al: Dual effects of daily FTY720 on human astrocytes in vitro: Relevance for neuroinflammation. J Neuroinflammation. 10:412013. View Article : Google Scholar : PubMed/NCBI
22	Yamagata K, Tagami M, Torii Y, Takenaga F, Tsumagari S, Itoh S, Yamori Y and Nara Y: Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia. 41:199–206. 2003. View Article : Google Scholar : PubMed/NCBI
23	Bauer J, Berkenbosch F, Van Dam AM and Dijkstra CD: Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. J Neuroimmunol. 48:13–21. 1993. View Article : Google Scholar : PubMed/NCBI
24	Merrill JE: Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: Normal and pathological. Dev Neurosci. 14:1–10. 1992. View Article : Google Scholar : PubMed/NCBI
25	Herx LM, Rivest S and Yong VW: Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J Immunol. 165:2232–2239. 2000. View Article : Google Scholar : PubMed/NCBI
26	Mason JL, Suzuki K, Chaplin DD and Matsushima GK: Interleukin-1beta promotes repair of the CNS. J Neurosci. 21:7046–7052. 2001.PubMed/NCBI
27	Arenas E, Trupp M, Akerud P and Ibáñez CF: GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron. 15:1465–1473. 1995. View Article : Google Scholar : PubMed/NCBI
28	Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA and Simpson LC; Simmons L, et al: GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 266:1062–1064. 1994. View Article : Google Scholar : PubMed/NCBI
29	Lin LF, Doherty DH, Lile JD, Bektesh S and Collins F: GDNF: A glial cell line-derived neurotrophic factor for midbrain dopa-minergic neurons. Science. 260:1130–1132. 1993. View Article : Google Scholar : PubMed/NCBI